Related Experiment Video

Updated: Aug 14, 2026

Inducement and Evaluation of a Murine Model of Experimental Myopia
07:20

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

Tropicamide (1%): an effective cycloplegic agent for myopic children

R E Manny1, M Hussein, M Scheiman

  • 1College of Optometry, University of Houston, 505 J. Davis Armistead Bldg., Houston, TX 77204-2020, USA. rmanny@uh.edu

Investigative Ophthalmology & Visual Science
|June 30, 2001
PubMed

Insights

One percent tropicamide effectively induces cycloplegia in children with myopia. This study found the drug

Area of Science:

  • Ophthalmology
  • Pediatric Ophthalmology
  • Clinical Trials

Background:

  • Myopia is a common refractive error in children.
  • Accurate refractive error assessment is crucial for myopia management.
  • Cycloplegic agents are used to relax accommodation for precise refraction.

Purpose of the Study:

  • To assess the efficacy of 1% tropicamide as a cycloplegic agent in myopic children.
  • To investigate potential associations between tropicamide's efficacy and demographic or refractive factors.

Main Methods:

  • A multicenter, randomized, double-masked trial involving 469 myopic children.
  • Administration of proparacaine followed by two drops of 1% tropicamide.
  • Measurement of accommodative responses using an autorefractor to determine residual accommodation.

Main Results:

  • 1% tropicamide demonstrated a significant cycloplegic effect in myopic children.
  • Mean residual accommodation was minimal (0.38 D OD, 0.30 D OS).
  • Ethnicity showed a statistically significant association with residual accommodation, unlike other factors.

Conclusions:

  • 1% tropicamide is a safe and effective cycloplegic agent for refractive examination in pediatric myopia.
  • The findings support the use of tropicamide for cycloplegic refraction in this population.
Abstract

More Related Videos

Binocular Dynamic Visual Acuity in Eyeglass-Corrected Myopic Patients07:06

Binocular Dynamic Visual Acuity in Eyeglass-Corrected Myopic Patients

Published on: March 29, 2022

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Related Concept Videos

Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...